Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned

Executive Summary

Pfizer relies on competition among research teams to help ensure that its vast R&D resources do not diminish the entrepreneurial spirit within the organization, CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 5 in New York City

You may also be interested in...



Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say

The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles

Biotech Model Benefit To Big Pharma Still Unclear, Former GSK Execs Say

The "jury is still out" on the value of large pharmaceutical companies imitating the structure of smaller biotech firms, former GlaxoSmithKline Biologicals VP-Global Clinical R&D Charles O'Bryan-Tear said April 18 at the Milken Institute Global Conference in Los Angeles

Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable

The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn

Related Content

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel